Integra LifeSciences (NASDAQ:IART) Trading Up 8.7% - Should You Buy?

Key Points

• Integra LifeSciences' stock rose 8.7% to $13.86, despite trading volume declining by 68% compared to the average daily volume.
• Analyst ratings are mixed, with Wells Fargo and JPMorgan reducing their price targets significantly, leading to a consensus rating of "Hold" and an average target price of $18.63.
• The company reported earnings of $0.45 per share, surpassing expectations, while revenue for the quarter was down 0.6% year-over-year at $415.61 million.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) rose 8.7% during trading on Tuesday . The stock traded as high as $13.85 and last traded at $13.86. Approximately 327,602 shares were traded during trading, a decline of 68% from the average daily volume of 1,015,415 shares. The stock had previously closed at $12.75.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities decreased their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Integra LifeSciences has a consensus rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Stock Up 8.3%

The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The firm has a market capitalization of $1.08 billion, a P/E ratio of -2.12, a PEG ratio of 0.73 and a beta of 1.16. The stock has a 50 day moving average of $12.60 and a 200-day moving average of $17.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%. The company had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same period in the previous year, the business earned $0.63 earnings per share. The firm's quarterly revenue was down .6% compared to the same quarter last year. Research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in shares of Integra LifeSciences by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock worth $9,542,000 after buying an additional 10,492 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Integra LifeSciences during the 1st quarter valued at $251,000. Victory Capital Management Inc. raised its stake in shares of Integra LifeSciences by 1,067.6% during the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after acquiring an additional 135,308 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after purchasing an additional 1,437 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Integra LifeSciences by 3,595.1% in the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after acquiring an additional 22,721 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.